ETV4 and prostate carcinoma: Estrogen treatment was once suggested as an alternative method to suppress testosterone in prostate cancer [24], and consistently, we found that the tamoxifen pathway was associated with ETV4-fusion-positive prostate cancer, and all genes related to the tamoxifen pathway were positively correlated with ETV4.